Imad Al-Naesan

Successful treatment of a necrotizing fasciitis related skin defect using fish skin grafting in a patient with extensive psoriasis vulgaris

Imad Al-Naesan, Nina Frischhut, Wolfgang Schlosser, Dietmar Pixner

at (code pays fourni par la source)

Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets

Simone Seyringer, Micha J. Pilz, Imad Al-Naesan, Madeleine King et autres

The Quality of Life (QoL) Utility measure, QLU-C10D, is derived of the European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire, QLQ-C30. Based on the cancer-specific nature, the QLU-C10D is expected to be sensitive and responsive in lung cancer patients.This …

at, au, be (code pays fourni par la source)

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Imad Al-Naesan, Daniela Krepper, Francesco Sparano, Monika Sztankay et autres

The objective of this study was to provide an overview of the current practice of patient-reported outcome (PRO) assessments in trials investigating treatment with BRAF inhibitors in patients with advanced melanomas. In addition, we extracted information on symptomatic adverse events (AEs) reported …

at, it (code pays fourni par la source)

Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs

Micha J. Pilz, Simone Seyringer, Imad Al-Naesan, Madeleine King et autres

BACKGROUND: Cost-utility analysis generally requires valid preference-based measures (PBMs) to assess the utility of patient health. While generic PBMs are widely used, disease-specific PBMs may capture additional aspects of health relevant for certain patient populations. This study investigates the construct and concurrent …

at, au, be (code pays fourni par la source)

Clinical Validity of the Cancer-Specific Utility Measure EORTC QLU-C10D: Retrospective Analyses of Four Lung Cancer Trials Using Six Country Tariffs.

Simone Seyringer, Micha J. Pilz, Imad Al-Naesan, Madeleine King et autres

at, au, de (code pays fourni par la source)

Information about missing patient-reported outcome data in breast cancer trials is frequently not documented: a scoping review

Daniela Krepper, Johannes M. Giesinger, Linda Dirven, Fabio Efficace et autres

OBJECTIVES: This review addresses the common problem of missing patient-reported outcome (PRO) data in clinical trials by assessing the current practice of their statistical handling as reported in publications of randomized controlled trials (RCTs) in patients with breast cancer. STUDY DESIGN AND …

at, nl, it (code pays fourni par la source)